Data presented for glecaprevir/pibrentasvir – a pan-genotypic regimen for the treatment of hepatitis C

Eight weeks of treatment with AbbVie’s investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P) achieved high SVR rates across all major genotypes of chronic hepatitis C

97.5 percent of chronic HCV infected patients without cirrhosis and new to treatment across all major genotypes (GT1-6) achieved SVR12 with 8 weeks of G/P

Across the 8-week arms of three registrational studies, no patients discontinued treatment due to adverse events

G/P is an investigational, pan-genotypic, once-daily, ribavirin-free regimen for the treatment of chronic HCV

To read the press release, click here.

Original Article